Clinical Outcomes of Aflibercept in AMD and DME

What clinical outcomes support aflibercept treatment of wet AMD and diabetic macular edema?

Aflibercept treatment for wet AMD and diabetic macular edema is supported by visual acuity improvements equivalent to ranibizumab and superior to laser photocoagulation, significant anatomical improvements including central retinal thickness reductions and diabetic retinopathy severity improvements, clinically meaningful quality of life gains, and a safety profile comparable to other anti-VEGF agents with the advantage of less frequent dosing.

Abstract

Aflibercept treatment for wet age-related macular degeneration produces visual acuity outcomes equivalent to ranibizumab, with both treatments showing similar mean BCVA changes (within 0.5 letters) and approximately 32% of patients gaining ≥15 letters at one year. Anatomical outcomes were also similar, with comparable proportions achieving dry retina (RR 1.06, 95% CI 0.98 to 1.14) and equivalent choroidal neovascularization area reductions. For diabetic macular edema, aflibercept demonstrated statistically significant superiority over laser photocoagulation, with mean BCVA gains of 10.5-13.6 letters compared to -0.5 to 1.2 letters for laser (p<0.0001), and central retinal thickness reductions of 183-195 μm versus 66-73 μm for laser (p<0.0001). At 148 weeks, 35.8-42.9% of aflibercept-treated eyes gained ≥15 letters versus 13.6-18.9% with laser. Aflibercept showed non-inferiority to bevacizumab (mean improvement 15.0 versus 14.0 letters, p=0.37) and better anatomical outcomes than ranibizumab in real-world practice (central subfield thickness reduction -114.4 μm versus -87.8 μm, p<0.01). Quality of life improved meaningfully in both conditions, with NEI VFQ-25 total score gains of +6.11 points in DME and clinically significant improvements across multiple subscales in wet AMD. The safety profile was comparable to other anti-VEGF agents, with serious systemic adverse events similar to ranibizumab (RR 0.99, 95% CI 0.79 to 1.25) and no new safety signals identified in long-term use. The every-8-weeks maintenance dosing regimen after initial loading reduced treatment burden compared to monthly regimens while maintaining efficacy.

Methods

We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 8 key aspects that mattered most to the research question.

Records from Elicit search

• n = 200
• Papers screened using: Target Population, Intervention, Clinical Outcomes, Study Design, Follow-up Duration, Aflibercept Analysis, Study Quality and Accessibility, Study Scope
• n = 200 Papers screened out
• n = 190 Papers included for extraction

Data extraction

Study Design

• Extract study design and population characteristics for aflibercept studies in wet AMD or diabetic macular edema:
  • Study type (RCT, observational, etc.)
  • Sample size and number of eyes treated with aflibercept
  • Patient population (wet AMD or diabetic macular edema or both)
  • Baseline disease characteristics (severity, prior treatment status)
  • Comparator group(s) if any (other anti-VEGF agents, laser, sham, etc.)
  • Follow-up duration

Visual Outcomes

• Extract all visual acuity and functional vision outcomes for aflibercept treatment in wet AMD or diabetic macular edema:
  • Best-corrected visual acuity (BCVA) changes from baseline (mean change in ETDRS letters)
  • Proportion gaining ≥15 letters
  • Proportion losing ≥15 letters
  • Proportion achieving specific visual acuity thresholds (e.g., ≥70 letters, 20/40 or better)
  • Low vision outcomes (proportion with vision worse than 20/200)
  • Statistical significance and confidence intervals
  • Time points assessed (52 weeks, 2 years, etc.)
  • Whether outcomes support aflibercept effectiveness

Anatomical Outcomes

• Extract morphological and anatomical outcomes for aflibercept in wet AMD or diabetic macular edema:
  • Central retinal thickness changes
  • Proportion achieving dry retina (absence of fluid)
  • Choroidal neovascularization area changes (for wet AMD)
  • Diabetic retinopathy severity scale improvements (for DME)
  • Statistical significance and effect sizes
  • Whether anatomical improvements support aflibercept treatment

Quality of Life

• Extract patient-reported outcomes and quality of life measures for aflibercept treatment in wet AMD or diabetic macular edema:
  • Vision-related quality of life scales (NEI VFQ-25 scores)
  • Functional vision assessments (near activities, distance activities)
  • Changes from baseline and clinical significance
  • Quality of life improvements support aflibercept use

Safety Profile

• Extract safety and adverse event data for aflibercept in wet AMD or diabetic macular edema studies, including:
  • Serious ocular adverse events (endophthalmitis, retinal detachment, cataract, etc.)
  • Serious systemic adverse events
  • Treatment-emergent adverse events by category
  • Rates and risk ratios compared to control groups
  • Long-term safety findings
  • Whether safety profile supports aflibercept use in these conditions

Treatment Regimen

• Extract aflibercept dosing and administration details for wet AMD or diabetic macular edema:
  • Dose administered (typically 2mg)
  • Initial loading schedule (e.g., monthly for 3-5 doses)
  • Maintenance schedule (e.g., every 8 weeks)
  • Treatment burden compared to other regimens

Comparative Effectiveness

• Extract comparative effectiveness data when aflibercept is compared to other treatments for wet AMD or diabetic macular edema:
  • Direct comparisons to ranibizumab, bevacizumab, or laser photocoagulation
  • Non-inferiority or superiority findings
  • Whether comparative data support choosing aflibercept over alternatives

Key Limitations

• Extract study limitations and factors affecting interpretation of aflibercept outcomes:
  • Risk of bias concerns (funding source, blinding, etc.)
  • Generalizability limitations (population, setting, exclusion criteria)
  • Any factors that might limit confidence in supporting aflibercept treatment

Results

Characteristics of included studies

The systematic review included 10 sources examining aflibercept treatment for wet age-related macular degeneration (AMD) and diabetic macular edema (DME). These comprised randomized controlled trials, observational studies, and systematic reviews.

The studies represented diverse designs, with five focusing on wet AMD and five on DME. Most studies were randomized controlled trials, with comparators including ranibizumab, bevacizumab, and laser photocoagulation. Follow-up durations ranged from 52 weeks to 3 years. Only two studies had full texts available for detailed extraction (J. Heier et al., 2012 and J. Carrasco et al., 2021).

Effects

Visual Acuity Outcomes in Wet AMD

Aflibercept demonstrated substantial and sustained visual acuity improvements in wet AMD across multiple studies. At one year, the mean change in BCVA was similar between aflibercept and ranibizumab groups (mean difference -0.15 ETDRS letters, 95% CI -1.47 to 1.17). This similarity persisted at two years, with mean changes of 7.2 letters for aflibercept versus 7.9 letters for ranibizumab.

Visual Acuity Outcomes in Diabetic Macular Edema

Aflibercept demonstrated consistent superiority over laser photocoagulation and non-inferiority to other anti-VEGF agents in DME. In the VISTA and VIVID trials, mean BCVA gains with aflibercept were 12.5 and 10.7 letters versus 0.2 letters with laser.

Anatomical Outcomes

Aflibercept produced significant anatomical improvements in both wet AMD and DME.

Vision-Related Quality of Life

Quality of life assessments demonstrated clinically meaningful improvements with aflibercept treatment.

Safety Profile

The safety profile of aflibercept was generally favorable and comparable to other anti-VEGF agents. Serious ocular adverse events were similar across aflibercept and ranibizumab treatment groups.

Treatment Regimens

Aflibercept was administered at a dose of 2 mg across all studies.

• Every 8 weeks regimen (2q8): Initial loading doses followed by maintenance dosing every 8 weeks.
• Treatment burden compared to other regimens shows reduced requirements.

Comparative Effectiveness

Aflibercept demonstrated non-inferiority to ranibizumab in wet AMD and superiority to laser photocoagulation in DME.